These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 26377838)

  • 1. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
    Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D
    Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening.
    Ting J; Smith JS; Myers ER
    J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary human papillomavirus testing in organized cervical screening.
    Dillner J
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):11-6. PubMed ID: 23299089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
    Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
    Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical cancer screening by cytology and human papillomavirus testing during pregnancy in French women with poor adhesion to regular cervical screening.
    Brun-Micaleff E; Coffy A; Rey V; Didelot MN; Combecal J; Doutre S; Daurès JP; Segondy M; Boulle N
    J Med Virol; 2014 Mar; 86(3):536-45. PubMed ID: 24114972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
    Campos NG; Castle PE; Wright TC; Kim JJ
    Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of primary cytology and HPV DNA cervical screening.
    Bistoletti P; Sennfält K; Dillner J
    Int J Cancer; 2008 Jan; 122(2):372-6. PubMed ID: 17935124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The health and economic effects of HPV DNA screening in The Netherlands.
    Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
    Holt HK; Zhang L; Zhao FH; Hu SY; Zhao XL; Zhang X; Pan QJ; Zhang WH; Smith JS; Qiao YL
    Int J Cancer; 2017 Feb; 140(3):544-554. PubMed ID: 27727464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus testing for primary screening of cervical cancer precursors.
    Ratnam S; Franco EL; Ferenczy A
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):945-51. PubMed ID: 11008913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing testing of the genuine savings hypothesis: The use of comprehensive measures of technical change for Ireland.
    McGrath L; Hynes S; McHale J
    J Environ Manage; 2024 Feb; 352():120072. PubMed ID: 38244413
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.
    Agapova M; Duignan A; Smith A; O'Neill C; Basu A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):999-1005. PubMed ID: 26377838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
    Holmes J; Hemmett L; Garfield S
    Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.